Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.51 |
| ▸ | CASR | P41180 | 3/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11991411 | 1.00 | AOC3 (0.51) | AOC3CASRACHEL3MBTL1TAAR1 | |
| SCHEMBL14284906 | 1.00 | AOC3 (0.51) | AOC3CASRACHEL3MBTL1TAAR1 | |
| SCHEMBL11991412 | 1.00 | AOC3 (0.51) | AOC3CASRACHEL3MBTL1TAAR1 | |
| SCHEMBL11619720 | 0.91 | CASR (0.53) | AOC3CASRACHEL3MBTL1TAAR1 | |
| SCHEMBL23544819 | 0.86 | CASR (0.57) | AOC3CASRACHEL3MBTL1TAAR1 | |
| SCHEMBL10446047 | 0.85 | AOC3 (0.53) | AOC3CASRACHEL3MBTL1TAAR1 | |
| SCHEMBL18793772 | 0.84 | AOC3 (0.54) | AOC3CASRACHEL3MBTL1TAAR1 | |
| SCHEMBL24925808 | 0.84 | AOC3 (0.54) | AOC3CASRACHEL3MBTL1TAAR1 | |
| SCHEMBL21286867 | 0.84 | AOC3 (0.54) | AOC3CASRACHEL3MBTL1TAAR1 | |
| SCHEMBL11615791 | 0.83 | AOC3 (0.51) | AOC3CASRACHEL3MBTL1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230053649-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230009608-A1 | GRK2 INHIBITORS AND USES THEREOF | SONATA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| WO-2022272036-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-11377422-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210246115-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | BIOIMICS AB (SE) | 2021-08-12 | — | — | US | disclosed |
| US-20210139479-A1 | COMT Inhibiting Methods and Compositions | LIEBER INST INC (US) | 2021-05-13 | — | — | US | disclosed |
| US-10934283-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-20210047329-A1 | SUBSTITUTED 4,6-DIHYDROSPIRO[[1,2,3]TRIAZOLO[4,5-B]PYRIDINE-7,3'-INDOLINE]-2',5(3H)-DIONE ANALOGUES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-02-18 | — | — | US | disclosed |
| US-20200290965-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
| US-7323490-B2 | Pyrrole compounds and uses thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2008-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047329-A1 | SUBSTITUTED 4,6-DIHYDROSPIRO[[1,2,3]TRIAZOLO[4,5-B]PYRIDINE-7,3'-INDOLINE]-2',5(3H)-DIONE ANALOGUES | DHPS, QDPR, HTR5A | AOC3 1039/4885CASR 4217/4885ACHE 1797/4885 |
| US-20210246115-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | FDPS, FPR1, F12 | AOC3 1092/4885CASR 4800/4885ACHE 813/4885 |
| US-20230009608-A1 | GRK2 INHIBITORS AND USES THEREOF | GRK2, GRK3, GRK1 | AOC3 3911/4885CASR 3385/4885ACHE 4754/4885 |
| US-11377422-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | AOC3 1327/4885CASR 433/4885ACHE 305/4885 |
| US-20210139479-A1 | COMT Inhibiting Methods and Compositions | COMT, PNMT, HNMT | AOC3 179/4885CASR 4738/4885ACHE 9/4885 |
| US-10934283-B2 | COMT inhibiting methods and compositions | COMT, MAOB, MAOA | AOC3 380/4885CASR 4451/4885ACHE 20/4885 |
| US-20200290965-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV2, TRPV5 | AOC3 1327/4885CASR 433/4885ACHE 305/4885 |
| US-20230053649-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | AOC3 3843/4885CASR 4045/4885ACHE 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.